Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt, Zymark Pen Automation Partnership

NEW YORK, March 4 - GeneProt has agreed to purchase four Zymark proteomics systems in an exclusive automation technology deal, the two companies said on Monday.


Under the terms of the arrangement, GeneProt will install two of Zymark's Staccato proteomics systems in its new North Brunswick, NJ facility, and two additional systems in its Geneva discovery and production center. The deal makes Zymark the sole provider of automation technology for GeneProt in the US and Europe.


Zymark will also get a nonexclusive license and right of first negotiation to GeneProt research discoveries in order to develop new consumable application kits. That use must not infringe upon GeneProt's own commercialization efforts or those of its partners in pharmaceuticals and diagnostics.


Zymark, based in Hopkinton, Mass., is also making an equity investment in GeneProt. Financial details of the deal were not disclosed.


The two companies said they also will jointly develop automation instruments: Zymark's proteomics system will be used to automate in-gel protein digestion, liquid handling steps, and protein and peptide-sample preparation for mass-spec analysis.


In December, GeneProt said that it was buying about $20 million worth of Micromass Q-Tof mass spec machines and services from Waters for its New Jersey facility.


That 100,000-square-foot center, projected to employ about 150 people, is now under construction. GeneProt expects it to open for business in the second quarter of 2002.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.